ALIGOS THERAPEUTICS INC has a total of 26 patent applications. Its first patent ever was published in 2019. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Taiwan. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are NURIX THERAPEUTICS INC, UNIV ESTADUAL PAULISTA JULIO DE MESQUITA FILHO UNESP and UNIV LEUVEN KATH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 11 | |
#3 | Taiwan | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Sugars | |
#5 | Microorganisms | |
#6 | Peptides | |
#7 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Beigelman Leonid | 17 |
#2 | Smith David Bernard | 12 |
#3 | Vendeville Sandrine | 10 |
#4 | Raboisson Pierre Jean-Marie Bernard | 8 |
#5 | Rajwanshi Vivek Kumar | 6 |
#6 | Hong Jin | 6 |
#7 | Mcgowan David | 5 |
#8 | Vandyck Koen | 5 |
#9 | Deval Jerome | 5 |
#10 | Debing Yannick | 5 |
Publication | Filing date | Title |
---|---|---|
US2020405743A1 | S-antigen transport inhibiting oligonucleotide polymers and methods | |
WO2021030278A1 | Bicyclic compounds | |
WO2020247504A1 | Heterocyclic compounds | |
WO2020243490A2 | Modified gapmer oligonucleotides and methods of use | |
US2020407361A1 | Tricyclic compounds | |
WO2020227549A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | |
US2020369711A1 | Modified cyclic dinucleoside compounds as sting modulators | |
US2020361947A1 | Bicyclic and tricyclic compounds | |
TW202102474A | Pyrrole compounds | |
US2020317686A1 | Compounds targeting prmt5 | |
US2020345749A1 | Bicyclic sulfonamides | |
WO2020097342A1 | S-antigen transport inhibiting oligonucleotide polymers and methods |